Akari Therapeutics Plc AKTX
Akari Therapeutics Plc (Nasdaq: AKTX) is an oncology drug developer. Its lead program, AKTX-101, is in Pre-clinical for Solid tumors (Trop-2 expressing; first-in-human planned in bladder cancer). Its next catalyst on record is AKTX-101: Advance into clinical trials (Phase 1 first-in-human) (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: AKTX-101 — Advance into clinical trials (Phase 1 first-in-human) (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Nomacopan (HSCT-TMA, PAS) | HSCT-TMA / PAS | protein/peptide | Phase 3 |
| AKTX-101 | Trop-2 positive solid tumors | antibody | Pre-clinical |
| AKTX-102 | CEACAM5 positive cancers | antibody | Pre-clinical |
| PHP-303 | — | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.